Meissa Vaccines Revenue and Competitors

Downtown Redwood City, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Meissa Vaccines's estimated annual revenue is currently $2.3M per year.(i)
  • Meissa Vaccines's estimated revenue per employee is $155,000

Employee Data

  • Meissa Vaccines has 15 Employees.(i)
  • Meissa Vaccines grew their employee count by -29% last year.

Meissa Vaccines's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP OperationsReveal Email/Phone
3
SVPReveal Email/Phone
4
VP Clinical DevelopmentReveal Email/Phone
5
VP Regulatory AffairsReveal Email/Phone
6
Senior Director, Head QualityReveal Email/Phone
7
Sr. Director Clinical OperationsReveal Email/Phone
8
Associate Director VirologyReveal Email/Phone
9
Chief Manufacturing OfficerReveal Email/Phone
10
Senior Director Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Meissa Vaccines?

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children's Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$2.3M

Revenue (est)

-29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Meissa Vaccines News

2022-04-13 - Covid nasal spray could replace vaccine jabs as scientists rethink fight against virus

Researchers at Meissa Vaccines in California use a version of the respiratory syncytial virus that has been weakened and covered with...

2022-04-06 - The next leap in coronavirus vaccine development could be a nasal ...

The next leap in coronavirus vaccine development could be a nasal ... Researchers at Meissa Vaccines in California use a version of the...

2022-03-30 - The Race to Reduce Covid-19 Transmission: An Update on 67 ...

Another example: one of the intranasal vaccines developed by NIH groups ... MV-014-212, Meissa Vaccines (USA), Viral vector (RSV), Phase 1

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.1M97-18%N/A